INO
Price
$0.38
Change
-$0.01 (-2.56%)
Updated
Sep 25, 6:59 PM EST
43 days until earnings call
MNKD
Price
$4.02
Change
-$0.04 (-0.99%)
Updated
Sep 25, 9:40 AM EST
44 days until earnings call

Analysis and predictions INO vs MNKD

Header iconINO vs MNKD Comparison
Open Charts INO vs MNKDBanner chart's image
Inovio Pharmaceuticals
Price$0.38
Change-$0.01 (-2.56%)
Volume$866.9K
CapitalizationN/A
MannKind
Price$4.02
Change-$0.04 (-0.99%)
Volume$381
CapitalizationN/A
View a ticker or compare two or three
INO vs MNKD Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
INO vs. MNKD commentary
Sep 25, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a StrongSell and MNKD is a StrongSell.

COMPARISON
Comparison
Sep 25, 2023
Stock price -- (INO: $0.39 vs. MNKD: $4.06)
Brand notoriety: INO: Notable vs. MNKD: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INO: 118% vs. MNKD: 79%
Market capitalization -- INO: $105.57M vs. MNKD: $1.09B
INO [@Biotechnology] is valued at $105.57M. MNKD’s [@Biotechnology] market capitalization is $1.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $410.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INO’s FA Score shows that 1 FA rating(s) are green whileMNKD’s FA Score has 3 green FA rating(s).

  • INO’s FA Score: 1 green, 4 red.
  • MNKD’s FA Score: 3 green, 2 red.
According to our system of comparison, MNKD is a better buy in the long-term than INO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INO’s TA Score shows that 4 TA indicator(s) are bullish while MNKD’s TA Score has 5 bullish TA indicator(s).

  • INO’s TA Score: 4 bullish, 4 bearish.
  • MNKD’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, INO is a better buy in the short-term than MNKD.

Price Growth

INO (@Biotechnology) experienced а -1.55% price change this week, while MNKD (@Biotechnology) price change was -6.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.06%. For the same industry, the average monthly price growth was +21.88%, and the average quarterly price growth was +34.12%.

Reported Earning Dates

INO is expected to report earnings on Nov 07, 2023.

MNKD is expected to report earnings on Nov 08, 2023.

Industries' Descriptions

@Biotechnology (-3.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for INO with price predictions.
OPEN
A.I.dvisor published
a Summary for MNKD with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MNKD($1.09B) has a higher market cap than INO($106M). MNKD YTD gains are higher at: -22.960 vs. INO (-74.756). MNKD has higher annual earnings (EBITDA): -14.06M vs. INO (-162.17M). INO has more cash in the bank: 195M vs. MNKD (144M). INO has less debt than MNKD: INO (30.8M) vs MNKD (289M). MNKD has higher revenues than INO: MNKD (158M) vs INO (9.62M).
INOMNKDINO / MNKD
Capitalization106M1.09B10%
EBITDA-162.17M-14.06M1,154%
Gain YTD-74.756-22.960326%
P/E RatioN/AN/A-
Revenue9.62M158M6%
Total Cash195M144M135%
Total Debt30.8M289M11%
FUNDAMENTALS RATINGS
INO vs MNKD: Fundamental Ratings
INO
MNKD
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
5
Undervalued
PROFIT vs RISK RATING
1..100
10029
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
9055
P/E GROWTH RATING
1..100
10029
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (5) in the Biotechnology industry is in the same range as INO (23) in the Medical Specialties industry. This means that MNKD’s stock grew similarly to INO’s over the last 12 months.

MNKD's Profit vs Risk Rating (29) in the Biotechnology industry is significantly better than the same rating for INO (100) in the Medical Specialties industry. This means that MNKD’s stock grew significantly faster than INO’s over the last 12 months.

INO's SMR Rating (97) in the Medical Specialties industry is in the same range as MNKD (100) in the Biotechnology industry. This means that INO’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Price Growth Rating (55) in the Biotechnology industry is somewhat better than the same rating for INO (90) in the Medical Specialties industry. This means that MNKD’s stock grew somewhat faster than INO’s over the last 12 months.

MNKD's P/E Growth Rating (29) in the Biotechnology industry is significantly better than the same rating for INO (100) in the Medical Specialties industry. This means that MNKD’s stock grew significantly faster than INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INOMNKD
RSI
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 4 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
84%
Momentum
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
81%
MACD
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 6 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 7 days ago
75%
Bullish Trend 14 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 4 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
79%
Aroon
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
75%
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AZMPX15.700.23
+1.49%
Virtus NFJ Emerging Markets Value P
CSHZX9.160.06
+0.66%
MainStay Cushing® MLP Premier I
JRAAX58.880.04
+0.07%
Janus Henderson Research A
USLYX59.30-0.07
-0.12%
JHancock US Global Leaders Growth R2
MENYX9.98-0.03
-0.30%
Madison Covered Call & Equity Income Y

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with IMGN. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then IMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
+1.86%
IMGN - INO
61%
Loosely correlated
-1.07%
MDGL - INO
56%
Loosely correlated
-3.87%
NTLA - INO
55%
Loosely correlated
-3.40%
CRSP - INO
54%
Loosely correlated
-1.24%
AXON - INO
53%
Loosely correlated
-0.36%
More

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with FOLD. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then FOLD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
-1.22%
FOLD - MNKD
51%
Loosely correlated
+0.41%
BEAM - MNKD
49%
Loosely correlated
-4.81%
AGIO - MNKD
49%
Loosely correlated
-1.49%
MDGL - MNKD
49%
Loosely correlated
-3.87%
EDIT - MNKD
48%
Loosely correlated
-1.88%
More